drugset / Trial / NCT05118906

Pilot Study on BP1.4979 Effect on Binge Eating Disorders

NCT05118906 ↗

Phase 2 Completed 67 enrolled Bioprojet
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This pilot study is to assess the efficacy and safety of BP1.4979 15 mg BID in female patients with moderate to severe binge eating disorder (BED), as defined according to DSM-5 guidelines.

Timeline

Start
2022-03-07
Primary completion
2025-08-14
Completion
2025-08-21

Drugs

EvaluationDrugModalityDoseRoute
Subject BP1.4979 Small molecule 15 mg —

Indications